Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been assigned an average rating of “Buy” from the twelve research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and two have given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $24.9091.

TRVI has been the subject of several recent research reports. BMO Capital Markets began coverage on Trevi Therapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $36.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Friday, July 17th. Stifel Nicolaus set a $30.00 price objective on Trevi Therapeutics in a research report on Friday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, May 20th. Finally, B. Riley Financial upped their target price on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a report on Monday, July 20th.

Hedge Funds Weigh In On Trevi Therapeutics

Institutional investors have recently modified their holdings of the company. KBC Group NV purchased a new position in shares of Trevi Therapeutics during the first quarter valued at approximately $29,000. Hilton Head Capital Partners LLC purchased a new stake in Trevi Therapeutics in the 4th quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd purchased a new stake in Trevi Therapeutics in the 4th quarter worth approximately $50,000. Russell Investments Group Ltd. raised its holdings in Trevi Therapeutics by 194.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after acquiring an additional 2,996 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Trevi Therapeutics by 32.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after acquiring an additional 1,523 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $18.40 on Friday. The firm has a 50 day simple moving average of $16.47 and a 200-day simple moving average of $13.71. Trevi Therapeutics has a 1-year low of $6.55 and a 1-year high of $20.22. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -57.50 and a beta of 1.00.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). On average, equities analysts expect that Trevi Therapeutics will post -0.47 earnings per share for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.